BCIRG 006: 10-Yr Follow-up of Adjuvant AC → T Compared With AC → TH and TCH for HER2+ Early BC

Slideset - This long-term follow-up analysis demonstrated a sustained advantage of adjuvant therapy with trastuzumab-containing regimens over the non-trastuzumab control in patients with HER2+ early breast cancer.
Source: Clinical Care Options Breast Cancer - Category: Cancer & Oncology Source Type: research